Henry S Friedman

USPTO Granted Patents = 10 (Patent Applications = 2)

CIPO Patents = 3

EPO Patents = 2 (Patent Applications = 2)

Average Co-Inventor Count = 2.9

ph-index = 3

Forward Citations = 35(Granted Patents)

Company Filing History:

Cornell Research Foundation Inc.

Johns Hopkins University

patents

where one patent can have more than one assignee

Years Active: 1995-2023

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11813298 - Oncolytic poliovirus for human tumors (2023-11-14),

2. 11406677 - Oncolytic poliovirus for human tumors (2022-08-09),

3. 10799543 - Oncolytic poliovirus for human tumors (2020-10-13),

4. 10744171 - Sequential anti-cancer treatment (2020-08-18),

5. 10398743 - Oncolytic poliovirus for human tumors (2019-09-03),

6. 6251886 - Methods of using temozolomide in the treatment of cancers (2001-06-26),

7. 5695751 - Enhancing delivery of large neutral amino acid drugs (1997-12-09),

8. 5523084 - Enhancing the anti-tumor effect of melphalan by prior administration of (1996-06-04),

9. 5407925 - Regional chemotherapy within the central nervous system with (1995-04-18),

10. 5407672 - Enhancing the anti-tumor effect of melphalan with L-amino acid oxidase (1995-04-18),

Title: The Innovative Contributions of Henry S. Friedman

Introduction

Henry S. Friedman is an esteemed inventor based in Durham, NC, recognized for his significant contributions to medical research and technology. With a prolific portfolio of 10 patents, he has pushed the boundaries of innovation in the field of oncolytic virotherapy, particularly in the context of human tumors.

Latest Patents

Friedman’s latest patents include groundbreaking work on an oncolytic poliovirus specifically designed for human tumors. This innovative chimeric poliovirus construct has shown remarkable anti-tumor effects during clinical trials. The mechanism of action involves both viral oncolysis and immune system recruitment, leading to necrosis in the tumor area. Remarkably, no adverse effects have been observed in the patients involved.

Career Highlights

Throughout his career, Friedman has worked with renowned institutions such as Duke University and the Cornell Research Foundation Inc., contributing to cutting-edge research and development in the medical field. His work has had a profound impact on cancer treatment methodologies, positioning him as a leading figure in oncology research.

Collaborations

Friedman’s achievements are bolstered by collaborations with other notable researchers, including Darell D. Bigner and Matthias Gromeier. Their combined expertise has facilitated groundbreaking advancements in the understanding and treatment of cancer using innovative viral therapies.

Conclusion

Henry S. Friedman exemplifies the spirit of innovation through his dedication to advancing cancer treatment. His patents and collaborations highlight a commitment to improving patient outcomes and developing novel therapeutic strategies. As he continues to push the envelope in research and development, his contributions will undoubtedly benefit the medical community and patients alike.

This text is generated by artificial intelligence and may not be accurate.